Eric B. Fastiff has practiced commercial litigation for the past 25 years, working on numerous cases involving the drug, food, technology, finance, and natural resource industries. He also represents businesses in commercial disputes with their suppliers and competitors. His clients include governments, Native American tribes and their health providers, businesses, individuals, and consumer groups.
Eric currently represents numerous Native American tribes and health providers seeking to recover damages the tribes suffered as a result of the Opioids and Juul epidemics.
Eric served as co-lead counsel in the California Cipro litigation, representing California consumers and third party payors in a state court class action lawsuit charging Bayer, Barr Labs, and other generic prescription drug manufacturers with a conspiracy to restrain competition in the sale of Bayer’s blockbuster antibiotic drug Ciprofloxacin, sold as Cipro. The 17-year litigation ultimately resulted in settlements totaling $399 million, a result the trial court described as “extraordinary.” Eric and the LCHB team’s work on the Cipro case led to recognition by California Lawyer and the Daily Journal as 2016 California Lawyers of the Year and receipt of the American Antitrust Institute’s 2017 award for Outstanding Private Practice Antitrust Achievement.
Eric also represents The Charles Schwab Corporation in a suit against several major banks for allegedly manipulating the London Interbank Offered Rate (LIBOR), and successfully led the prosecution of a two week arbitration on behalf of a client that alleged both intellectual property and breach of contract claims. Eric’s notable successes include representing businesses that purchased TFT-LCD panels and products in litigation charging that the world’s leading TFT-LCD manufacturers conspired to fix prices. The litigation resulted in settlements totaling over $470 million.
Long form bio (click to open pdf).